Regulatory
Vericel Corporation reported financial results for the first quarter ended March 31, 2019, and recent business highlights.
The Global Health Investment Fund (GHIF) and Medicines Development for Global Health (MDGH) announced the sale of MDGH’s Priority Review Voucher (PRV).
ADL Bionatur Solutions advances the results of selected key performance indicators for the first quarter of 2019 ending March 31, 2019.
Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.
PDC*line is a potent, scalable and versatile professional antigen-presenting T-cell with great potential for treating a range of cancers
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States
On March 27, the U.S. Food and Drug Administration (FDA) approved Novartis’ Mayzent (isiponimod) for adults with relapsing types of multiple sclerosis.
The Jacobus LEMS Drug was approved for pediatric patients. However, the approval was based on results from a study of adult patients, which means that doctors could opt to prescribe this medication for adult LEMS patients.
Invitrocue Limited is pleased to provide its Appendix 4C cash flow statement for the quarter ended March 31, 2019 and to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.
Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver
PRESS RELEASES